CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » BLOGS

STRAIGHTFORWARD ONCOLOGY 

Hormones. Hormones? Hormones!

By Rebecca Bechhold, MD1 | March 6, 2013
1Medical Oncologist, Cincinnati, Ohio

It used to be so easy. Patients with ER-positive breast cancer got 5 years of tamoxifen(Drug information on tamoxifen). You could anticipate most of the side effects, explain it, patients were happy not to be on chemotherapy. No one showed up with an armload of internet downloads ready to debate the utility of hormone therapy, the risks, and metabolism or drug interactions.

Rebecca Bechhold, MD

No more. Now we have (thankfully) aromatase inhibitors for postmenopausal patients. We currently use 5 years, but I know there are doctors who just leave high-risk women on them “for life.” The extension trial data is not out yet, but the recent ATLAS trial tells us to leave tamoxifen patients on that drug for 10 years.

(MORE: I Can’t Talk to You With a Gun in My Face)

What are you doing with the T1a N0, strongly ER-positive patient who just finished 5 years of tamoxifen? I know I am having a lot of long talks with my patients about what is right for them. I honestly do not have strong confidence I know what the best practice for every scenario is. Much of it is dictated by the way the patient has tolerated tamoxifen and how committed they are to continuing it for another 5 years.

Thankfully, many patients who ask about it are barely into their first 5 years so we can forgo that decision for a bit as the data shakes out. Some changes I jump into, others not so much. You?

CYP2D6. Somebody please answer that question decisively and permanently! Do we need to test all patients for genetic alterations? Matthew Goetz, MD, of the Mayo Clinic, would say yes. Do we have to change their antidepressants? Does it make a difference in survival? If you are an extensive metabolizer, can you just take tamoxifen for 5 years (or maybe 10) and not switch to an aromatase inhibitor? We need to know. I cannot get a consensus among my own partners, one of whom did estrogen receptor research before going into clinical practice. We need the Ten Commandments of hormonal therapy. What gives the best outcome for our patients? What are premenopausal women supposed to do if they are poor metabolizers?

Hormone therapy is apparently a new gold mine. You must have the same TV ads in your area. We have multiple “natural hormone” replacement practices and the ads are all the same theme. The woman sits with her husband behind her and talks about how her life has changed with natural hormone therapy. She openly declares and her husband confirms that she is now hot all the time, but not from hot flashes. She also predicts that she is going to lose that extra weight she has been carrying for the last 40 years, plus she is going to get her college degree and land her dream job! The fact that she is 55 to 65 years old and had plenty of estrogen coursing through her veins all those premenopausal years, and yet never lost her postpartum pounds and never exhibited a passing interest in furthering her education should not detract from the message that hormone therapy will make your life amazing.

I have yet to see any small print disclaimer at the bottom of the screen about the risks of hormone therapy. If that were a pharma company making such claims you know they would be required to have a host of small print and fast talking actors to “balance” the message. Why are the hormone palaces allowed such unbridled freedom? New breast cancer patients still come in and say they have been on hormone therapy for 10, 15, 20 years and when asked what it was originally started for it is sometimes for severe hot flashes, but one woman told me last week that her doctor told her if she didn’t take it she would “look like an old woman” in a few years. Oh, well in that case.

We now have low T clinics here. If Victoria’s Secret didn’t have so many catalogs, maybe there wouldn’t be such so many feelings of inadequacy. But, again, how are they allowed to manipulate consumers to seek prescriptions for drugs with such unrestrained, unregulated messages.

We all want our patients to be healthy and happy. If I prescribe a medication, I want to feel confident that I am offering a necessary treatment and that I have educated the patient about the risks and benefits. That is why we all want the best information on how to proceed with hormonal manipulation for breast cancer patients.

I look forward to your comments and advice.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by elena perrotta | March 25, 2013 9:24 PM EDT

Thank you for your honest comments regarding the reality of menopause. As an oncology nurse, I have seen far too many women die from breast and reproductive cancers. I went through menopause at the age of 47. I took HRT for one year. I decided to stop after experiencing leg cramps. It has been four years with no OTC remedies. I have seen my weight increase by 10 lbs. I have developed some arthritis and I suffer from some insomnia and hot flashes. I have lost my sex drive. I feel however that this is a natural aging process and I will late nature take its course.
I try to eat right and exercise when I can and that is the best remedy along with meditation, spirituality, and rest.

by Marcia Dietrich | March 08, 2013 9:14 AM EST

Since we cannot yet predict with any confidence who might get breast cancer, and we know breast cancer can be
hormone dependent, why are there any advertisements for hormone treatment? Does corporate greed override
any medical ethics?

by FW Danby | March 07, 2013 10:45 PM EST

Wiebe has shown that estrogen receptors multiply in the face of exposure to 5 alpha pregnanedione, which is present in milk. It is a precursor of the androgen DHT and despite all the fuss about E+ tumors, the fact is that 82% of most common breast cancers are T+. Using Tamox has logical and predictable results (including the low E side effects). But where is the incentive to stop the dairy that contains the 5 alpha P that increases the E+ receptors and the milk also contains E that then (likely) stimulates tumor growth.
Bottom line - why the huge $$$$ spent on treatment when avoiding the exogenous hormones that (likely) drive tumor growth can be so easily avoided?
Let me have your real email address for attachments and I'll send along some PDFs
I sometimes wonder if the influence of industry leads to a focus on money-generating approaches instead of cancer-prevention efforts.
Is Susan B being misled?

by Rebecca Bechhold | March 07, 2013 6:42 PM EST

Alvin, I am so sorry for your loss. It must have been devastating and highly traumatic for you to write a book about your experience.

Patricia- I don't think any of us know what we do if we were in the position of the patient. You raise very good questions and I think many times the answer is not a guideline but what do we think is the biology of the individual tumor. It also depends on how much treatment or nontreatment the patient can tolerate physically and emotionaly.I am not a fan of tamoxifen or AI's for very small cancers after bilateral mastectomy, but it does depend on your definition of small and what the ER/PR levels were.

Barbara- I could not agree with you more!

Thank each of you for your insight and comments.

by Patricia Rosen | March 07, 2013 4:08 PM EST

as a patient and a physician: I still don't have the answer on aromatase inhibitors. is it really necessary to treat with meds forever? or even for 5 years? for A1N0. how do you know the aches and pains from the aromatase inhibitor aren't normal aches and pains of routine physical activity?

If you have had a bilateral mastectomy for a small cancer, do you really have to take Tamoxifien?

any answers to this question are appreciated.

Article Comment Pages: 1 2 Next


Straightforward Oncology

What Is a Meaningful Increased Survival?

Hormones. Hormones? Hormones!

“How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”

I Can’t Talk to You With a Gun in My Face






 
MORE BLOGS

Pain or Feign?
June 10, 2013
50 Shades of Pink—And Why It Helps to Know the Difference
May 17, 2013
I Can’t Talk to You With a Gun in My Face
May 3, 2013
“This Is My Last Day on Earth”
May 2, 2013
Conflicts of Interest in Medicine: What About Ties to Payers?
April 5, 2013
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy